Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

COMPLETED Phase 2

A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy

NCT02435862 · View on ClinicalTrials.gov ↗

Study Summary

A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.

Interventions

  • DRUG 1.0mg Luminate®
  • DRUG 2.0mg Luminate®
  • DRUG 3.0mg Luminate®
  • OTHER Balanced Salt Solution for intravitreal injection in 0.10cc

Study Locations (12)

Texas

  • Retina Research Institute Of Texas — Abilene
  • Austin Retina Associates — Austin
  • Valley Retina Institute — McAllen
  • Medical Center Ophthalmology Associates — San Antonio

California

  • Northern California Retina Vitreous Associates — Mountain View
  • UCI Medical Center — Orange

Connecticut

  • New England Retina Associates — New London

Florida

  • Center for Retina and Macular Disease — Lakeland

Illinois

  • Illinois Retina Center — Springfield

Indiana

  • Midwest Eye Institute — Indianapolis

Virginia

  • The Retina Group of Washington — Fairfax

Washington

  • Spokane Eye Clinical Research — Spokane

Trial Details

FieldValue
Enrollment Target 105 participants
Start Date 2015-02-01
Est. Completion 2017-08-10
Phase Phase 2

Sponsor

Allegro Ophthalmics

2 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02435862

The ClinicalTrials.gov registry entry for NCT02435862 describes a study currently listed as completed. It is categorized as Phase 2, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 105 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Allegro Ophthalmics, which has 2 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Non-Proliferative Diabetic Retinopathy appearing as the primary indexed condition, and to 4 interventions — of which 1.0mg Luminate® is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT02435862 reports 12 study locations spanning 8 distinct geographic areas — top geographies include Texas, California, Connecticut. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT02435862 about?

NCT02435862 is a clinical study titled "A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy". A Phase 2, Randomized, Double-masked, Placebo-controlled Multicenter Clinical Trial Designed to Evaluate the Safety and Efficacy of Luminate in Inducing PVD in Subjects with Non-Proliferative Diabetic Retinopathy.

What is the current status of trial NCT02435862?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 105 participants. The study started on 2015-02-01. Estimated completion is 2017-08-10.

What conditions does trial NCT02435862 study?

This clinical trial studies the following conditions: Non-Proliferative Diabetic Retinopathy. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT02435862?

The interventions under investigation include: 1.0mg Luminate® (DRUG), 2.0mg Luminate® (DRUG), 3.0mg Luminate® (DRUG), Balanced Salt Solution for intravitreal injection in 0.10cc (OTHER). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT02435862?

This trial is sponsored by Allegro Ophthalmics, which has 2 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT02435862 being conducted?

This trial has 12 study locations across California, Connecticut, Florida, Illinois, Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial